Stockscreener 앱 받기
13.12
2.09%
-0.28
시간 외 거래:
13.12
Tourmaline Bio Inc 주식(TRML)의 최신 뉴스
Tourmaline Bio: We Should Wait For Upcoming Phase 2b Trial Data - Seeking Alpha
Should You Invest in H&R Block Inc (HRB) Now? - News Heater
Swiss National Bank Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Leading Factor Driving the Thyroid Eye Disease (TED) Market in 2025: Thyroid Disorders And Their Influence ... - WhaTech
ProfittoPath - TradingView
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Sold by AlphaQuest LLC - Defense World
Tourmaline Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Tourmaline Bio (NASDAQ:TRML) Stock Price Expected to Rise, Wedbush Analyst Says - Defense World
HC Wainwright Raises Tourmaline Bio (NASDAQ:TRML) Price Target to $50.00 - Defense World
H.C. Wainwright raises Tourmaline Bio stock target to $50 By Investing.com - Investing.com Canada
Tourmaline Bio price target raised to $43 from $42 at Wedbush - TipRanks
H.C. Wainwright raises Tourmaline Bio stock target to $50 - Investing.com India
Wedbush Lifts Price Target on Tourmaline Bio to $43 From $42, Keeps Outperform Rating - Marketscreener.com
Tourmaline Bio shares fall as Q4 loss widens By Investing.com - Investing.com Australia
Tourmaline Bio’s 2024 Financial Results and Strategic Advances - TipRanks
Tourmaline Bio shares fall as Q4 loss widens - Investing.com
TOURMALINE BIO Earnings Results: $TRML Reports Quarterly Earnings - Nasdaq
Tourmaline Bio, Inc. SEC 10-K Report - TradingView
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Tourmaline Bio's cash position to provide cash runway into second half of 2027 -March 13, 2025 at 07:39 am EDT - Marketscreener.com
Tourmaline Bio, Inc. Announces Over-Enrolled Phase 2 TRANQUILITY Trial and Strengthens Cardiovascular Scientific Advisory Board Amid Positive Financial Outlook - Nasdaq
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business - Bluefield Daily Telegraph
Tourmaline Bio Secures 2.5-Year Cash Runway with $294M, Accelerates Key Clinical Trials - StockTitan
Tourmaline Bio (TRML) Projected to Post Earnings on Tuesday - Defense World
Wedbush Forecasts Tourmaline Bio FY2024 Earnings - Defense World
Tourmaline Bio (NASDAQ:TRML) Research Coverage Started at Wedbush - Defense World
Rhumbline Advisers Has $722,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio rises as Wedbush initiates with Outperform - MSN
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - NewsBreak
Wedbush bullish on Tourmaline Bio, initiates with an Outperform - TipRanks
Wedbush Initiates Coverage on Tourmaline Bio With Outperform Rating, $42 Price Target - Marketscreener.com
Wedbush Initiates Tourmaline Bio at Outperform With $42 Price Target -March 06, 2025 at 07:22 am EST - Marketscreener.com
We Tested Over 25 Curling Irons. These 13 Are the Best - MarieClaire.com
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
Volatus Aerospace and Draganfly Expand Collaboration to Service High-Value Geospatial Power Utility Customers - The Manila Times
3 Reasons to Buy American Express Stock Like There's No Tomorrow - The Globe and Mail
When and Where to Catch Tourmaline Bio's Next Investor Presentation - StockTitan
Brokers Set Expectations for Tourmaline Bio FY2024 Earnings - MarketBeat
Truist maintains $74 target on Tourmaline Bio stock, reiterates buy By Investing.com - Investing.com UK
Lifesci Capital Predicts Tourmaline Bio FY2024 Earnings - Defense World
Financial Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) - Defense World
Lifesci Capital Initiates Coverage on Tourmaline Bio (NASDAQ:TRML) - Armenian Reporter
Tourmaline Bio (NASDAQ:TRML) Coverage Initiated by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Tourmaline Bio (TRML) with Outperform Recommendation - MSN
Talaris Therapeutics stock hits 52-week low at $12.06 By Investing.com - Investing.com Australia
Talaris Therapeutics stock hits 52-week low at $12.06 - Investing.com
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Vaxcyte (NASDAQ:PCVX) & Tourmaline Bio (NASDAQ:TRML) Financial Review - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $54.00 Average PT from Brokerages - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of “Buy” by Analysts - Defense World
ClearOne (NASDAQ:CLRO) Earns Hold Rating from Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on Bank of South Carolina (NASDAQ:BKSC) - Defense World
Aethlon Medical (NASDAQ:AEMD) Raised to Sell at StockNews.com - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Short Interest Up 16.3% in January - MarketBeat
Vulcan Materials (VMC) Q4 Earnings: What To Expect - The Globe and Mail
TrueBlue (TBI) Expected to Announce Earnings on Wednesday - Armenian Reporter
1.23%
1.63%
자본화:
|
볼륨(24시간):